Abstracts who suffered a VTE event and those that did not. Risk adjustment was done using propensity score matching (using the ProbChoice TM algorithm) controlling for baseline demographic and clinical characteristics between patients with and without VTE.
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STATinMED Research, Ann Arbor, MI, USA, 2 STATinMED Research / University of Michigan, Ann Arbor, MI, USA OBJECTIVES: To estimate re-hospitalization and bleeding rates during the 90 days after a venous thromboembolism (VTE) event in patients who underwent knee replacement surgery and to compare the outcomes with patients who did not suffer VTE. METHODS: Based on 2005-2007 national Medicare claims, all patients who underwent knee replacement surgery were identified. The 90 days follow-up event rates for patients who had a VTE event during their initial hospitalization were calculated. Events were compared between patients who suffered a VTE event and those who did not. Risk adjustment was done using propensity score matching (using the ProbChoice TM algorithm) controlling for baseline demographic and clinical characteristics between patients with and without VTE. RESULTS: In patients who underwent total knee replacement surgery (n = 104,952), 1.9% had post-operative VTE events during their initial hospitalization. Almost 69% (n = 1377) of these patients had deep vein thrombosis (DVT), 25% (n = 501) had pulmonary embolism (PE), and 6% (n = 119) had both DVT and PE. The overall likelihood of mortality was four times higher for VTE patients versus those without VTE (1.35% vs. 0.35%). Patients with VTE during their initial hospitalization were more likely to be hospitalized in 90 days (compared to patients without an event during the same hospital stay (16.62% vs. 8.00%). In 90 days after the event, patients with VTE were more likely to have bleeding (10.17% vs. 2.68%). CONCLUSIONS: VTE events during initial hospitalization for total knee replacement surgery increased the adverse events compared with no VTE events. patients who underwent hip fracture surgery were identified. The 30 days follow-up event rates for patients who had a VTE event during their initial hospitalization were calculated. Events were compared between patients who suffered a VTE event and those who did not. Risk adjustment was done using propensity score matching controlling for baseline demographic and clinical characteristics between patients with and without VTE. RESULTS: In patients who underwent hip fracture surgery (n = 50,245), 1.5% had post-operative VTE during their initial hospitalization. Almost 77% (n = 573) of these patients had deep vein thrombosis (DVT), 20% (n = 141) had a pulmonary embolism (PE), and 3% (n = 34) had both DVT and PE. Patients with VTE during their initial hospitalization were more likely to be hospitalized in 30 days (compared to patients without an event during the same hospital stay (32% vs. 6.82%). In 30 days after the event, patients with VTE were more likely to have bleeding (10.65% vs. 0.68%). CONCLUSIONS: VTE events during initial hospitalization for hip fracture surgery patients increased the adverse events compared with no VTE events. The aim of this study was to conduct a meta-analysis of randomized clinical trials (RCTs) to identify the effectiveness and safety of atorvastatina (20 mg-80 mg) against pravastatin, simvastatin and rosuvastatin. METHODS: A systematic review was performed including RCTs in primary and secondary prevention where total cholesterol, LDL-C, HDL-C, major cardiovascular events, as well as adverse events frequency werw analyzed. RCTs were searched in March 2009 in Medline, EMBASE and the Cochrane Collaboration. Two independent reviewers identified the abstracts, selected the full articles, and extracted the data. Odds ratios (OR) and weighted means differences were calculated with 95% confidence intervals (95%CI). Random effects models were employed in the Meta-analyses using RevMan v.5.0 software. RESULTS: From 7539 studies, 66 RCT were selected. Atorvastatin showed statistically a higher improvements in LDL-C, total cholesterol, HDL-C and triglycerides in comparison to pravastatin and simvastatin (5%-15%). Rosuvastatin was statistically superior against atorvastatin in LDL-C and total cholesterol, however not in HDL-C and triglycerides (p < 0.01). Atorvastatin obtained higher reductions in acute myocardial infarctions (AMI), unstable angina, and revascularizations in comparison to pravastatin and simvastatin (p < 0.05). Atorvastatin 80 mg showed in comparison to pravastatin 40 mg a higher reduction of mayor cardiovascular events (OR 0.87; 95%CI 0.77-0.97, p = 0.01), revascularization (OR 0.86; IC95% 0.76-0.98, p = 0.02) and unstable angina (OR 0.74; 95%CI 0.57-0.95, p = 0.02); nevertheless no statistical differences were found for AMI or cardiovascular death. Rosuvastatin requires data on cardiovascular events prevention in order to be compare appropriately against atorvastatin. The frequency of adverse events resulted similar among all the statins considered in the assessment. CONCLUSIONS: Atorvastatin in comparison to pravastatin and simvastatin showed a higher control of dyslipidemia and a better reduction of major cardiovascular events, without increasing the frequency of adverse events.
PCV5 ADVERSE EVENT ANALYSIS FOR MEDICARE PATIENTS WHO UNDERWENT HIP FRACTURE SURGERY AND SUFFERED VENOUS THROMBOEMBOLISM
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PCV7 INCIDENCE AND OUTCOMES OF POTENTIAL DRUG-DRUG INTERACTIONS BETWEEN ACE/ARB AND POTASIUM SPARING DIURETICS
Banahan III BF, Mendonca CM, Athavale A, Bentley JP University of Mississippi, Oxford, MS, USA OBJECTIVES: To examine incidence of and the health outcomes associated with potential drug-drug interactions (DDIs) between ACE/ARBs and potassium sparing diuretics among Medicaid patients. METHODS: A retrospective matched cohort study was conducted of beneficiaries in the Mississippi Medicaid program from January 2002 to December 2004. Potential DDIs were defined as medication possession data indicating an object drug (ACE/ARB) and a precipitant drug (potassium sparing diuretic) were taken with overlapping dates. The first day of overlap was designated as the DDI index date. A 6-month washout period was used for exposures. Exposed patients were matched 1-1 to controls taking ACE/ARBs and assigned the same index date. Exact matching was done on sex, race, CHF comorbidity, and cerobrovascular disease comorbidity and close matching was done for age (±10) and first use date for ACE/ARB (±45). Outcomes included hospitalizations and ER visits within 30 days of the index date and payments associated with these services. RESULTS: A total of 68,299 patients were identified as taking ACE/ARBs during the observation period with 5572 (8.4%) exposed to a potential DDI. A total of 5599 exposed patients were matched. The effect of DDI exposure on hospitalization and ER visit rates was tested using SAS fixed effects logistical regression while controlling for sex, age, race and overall Charlson comorbidity index. The point-specific odds ratio for DDI exposure was 1.41 (95% CI = 1.29 − 1.54) for hospitalization and 1.21 (95% CI = 1.11 − 1.31) for ER visits. A paired t-test was used to examine differences in Medicaid payments during the 30-days after the index date. Total payments were significantly higher (p < 0.001) for the exposed patients ($2289) than for the control patients ($1,614). CONCLUSIONS: Potential ACE/ARB DDIs were a significant problem among the Mississippi Medicaid patients and during the study period; potentially contributing more than $3.7M in additional health care costs.
PCV9 CLINICAL RELEVANCE OF PHARMACOLOGICAL INTERACTIONS
Head Association of the Austrian Social Insurance Companies, Vienna, Austria, 2 VISEM-Vienna School of Evidence Based Medicine, Vienna, Austria OBJECTIVES: Adverse events -Aes-due to medication errors are numerous. One type of error is the combination of substances with a known unwanted pharmacological interaction. In the years 2001 to 2006 a total of 39521 AEs with ICD10 codes indicating drugs as reason where documented in Austrias hospitals. There is no reporting system or documentation for adverse events in ambulatory care. So the rate of AEs in the outpatient setting is unknown. One of the main projects in Austrias e-health roadmap is an e-medication system. Due to the foreseeable costs an estimation and calculation of potential benefits is mandatory. METHODS: We use reimbursement data of the Austrian social insurance companies covering the years 2006 and 2007. The domains included are pharmaceutical reimbursement, reimbursement of outpatient medical services, hospital reimbursement data and sick leave data. We focus on interactions between the following pharmaceutical groups: 1. ATC code C10AA-statins, 2. ATC code N5BA-benzodiacepins, 3. ATC code J01FA makrolide antibiotics and 4. ATC code C01BD amiodarone. RESULTS: The main question to answer is the prevalence and incidence of such interaction patterns. This will lead to a description of the epidemiology of potential AEs which can at least be qualified as medical errors. The second question is the frequency of clinical relevant interactions. A clinical (and economic) relevance is ascertained, if the interaction needs medical treatment. The detection of outcomes of an interaction is the main challenge. CONCLUSIONS: The extent to which an e-medication system can improve patient safety can be esti-mated. Therefore prescriptions causing interaction coming from one office should be prevented. But prescriptions from different offices cannot be avoided by the use of this isolated solution. Only a comprehensive e-health solution summoning up medication of a patient from different sources has the potential to improve patient safety. There are pharmacologic interactions with different clinical relevance.
PCV10 A META-ANALYSIS OF CARDIOVASCULAR RISK FACTORS: WHICH IS THE DIFFERENCE BETWEEN MEN AND WOMEN?
Villasis-Keever MA 1 , Rendón-Masías ME 1 , Pineda-Cruz R 1 , Escamilla-Nuñez A 1 , Mould-Quevedo JF 2 1 Instituto Mexicano del Seguro Social, Mexico City, Mexico, Mexico, 2 Pfizer S.A. de C.V., México City, Mexico OBJECTIVES: The aim of this study was to conduct a meta-analysis to identify the potential differences of cardiovascular risk factors between men and women in primary prevention. METHODS: A systematic review was performed identifying prospective cohorts studies in which cardiovascular risk factors were analyzed (tobacco use, hypertension, diabetes, obesity and dyslipdemia) associated to the development of acute myocardial infarction, angina pectoris or cardiovascular death, and in which results were segmented between men and women. The search was done in October 2009 in Medline, EMBASE and the Cochrane Collaboration. Two independent reviewers identified the abstracts, selected full articles and extracted the data. Relative risk(RR) with 95% confidence intervals (95%CI) were calculated. Random effects models were employed in the meta-analyses using Meta-Analyst v.2.0 software. A meta-regression was also conducted. RESULTS: From 3,712 studies, 21 cohort studies were selected. The number of participants among the trials varied between 5,000 and 600,000 per study with a follow-up from 5 to 40 years. The meta-analyses showed that premenopausal women in comparison to men had a higher risk of having cardiovascular event when they have diabetes mellitus (RR 2.79 vs. 2.03), obesity (1.62 vs. 1.41), hypercholesterolemia (1.91 vs. 1.49), increase in LDL levels (2.08 vs. 1.72) or increase in HDL levels (2.22 vs. 1.61); however, men showed higher risk of cardiovascular events when they have hypertension (RR 1.771; 95%CI 1.714-1.830 vs. RR 1.812; 95%CI 1.759-2.305). In addition, women use of contraceptives was not a significant cardiovascular risk factor. CONCLUSIONS: The majority of cardiovascular risk factors seem to be higher in premenopausal women rather than men. Preventive programs should include female population in other to avoid a greater number of cardiovascular events in the future.
PCV11 IDENTIFYING RISK FACTORS ASSOCIATED WITH DISEASE BURDEN IN PATIENTS WITH TYPE II DIABETES AND COMORBID CARDIOVASCULAR DISEASE
Nichol MB 1 , Wu J 1 , An JJ 1 , Knight TK 1 , Priest J 2 , Cantrell C 2 1 University of Southern California, Los Angeles, CA, USA, 2 GlaxoSmithKline, RTP, NC, USA OBJECTIVES: To evaluate 1) use of diabetes and cardiovascular medications; 2) the associations of medication compliance with disease burden. METHODS: California Medicaid administrative data (2002) (2003) (2004) were used to identify patients ≥40 years of age with a diagnosis of type II diabetes concurrent with any combination of the following cardiovascular diseases (CVD): hypertension (HYPT), coronary artery disease (CAD), and heart failure (HF). We assessed patients use of any appropriate diabetes or cardiovascular medication. Proportion of days covered ≥0.8 was used to evaluate medication compliance. Disease burden was defined as any emergency or inpatient visit. Logistic regressions were used to identify factors associated with disease burden in 2004. RESULTS: We identified 21,740 patients. Fifty-six percent of patients filled both diabetes and cardiovascular medications. When compared to patients with comorbid HYPT(51%), those with two CVD conditions HF & CAD(69%) or HYPT & CAD(64%) were more likely to fill both diabetes and cardiovascular medications (P < 0.0001). Approximately 43% of patients did not fill or were noncompliant with appropriate medications. 
20). CONCLUSIONS:
Prevalence of use for both appropriate diabetes and cardiovascular medications was low in diabetic patients with comorbid CVD. We identified multiple risk factors of disease burden, primarily those related to condition severity (based on proxy measures of comorbidity with two CVD or filling both diabetes and CVD medications), as well as not using or not complying with medications.
PCV12 TRENDS IN C-REACTIVE PROTEIN SCREENING PRIOR TO STATIN USE IN THE UNITED STATES
Slejko JF, Anderson HD, Valuck RJ University of Colorado Denver, Aurora, CO, USA OBJECTIVES: The objective of this study was to explore trends in high sensitivity C-reactive protein (hs-CRP) screening prior to statin use, as compared to current lipid screening practices. METHODS: The PharMetrics Integrated Outcomes Database was used to obtain medical claims records for continuously enrolled adult (≥18 years) first-time statin users. Patients were followed for one year. Both hs-CRP and lipid tests were identified by CPT-4 procedure codes. Descriptive statistics were used to characterize the population and estimate unadjusted associations between patient characteristics and hs-CRP testing. Multivariable logistic regression was used to estimate the odds of testing, controlling for age, gender, diabetes, statin intensity, prescribing physician specialty, geographic region and health plan type. RESULTS: Between July 1, 1997 and March 31, 2007, 33,666 new statin users received lipid tests within 90 days prior to the index statin prescription. One thousand (3%) also received hs-CRP tests during this time. Over 80% of these individuals received the tests in 2004 or later. Those receiving hs-CRP tests were less likely to have a Medicare, Medicaid or other type of plan, as compared to private insurance (P < .05) and were less likely to reside in the South, Midwest or West, as compared to the Northeast (P < 0.01). Individuals who received hs-CRP tests had higher adjusted odds of receiving a high potency statin (OR = 1.37, P < .01) and lower odds of having diabetes (OR = 0.56, P < 0.01). Those receiving hs-CRP tests were more likely to have a cardiologist as their statin-prescribing physician, rather than a family or general practitioner (OR = 1.31, P = 0.02). CONCLUSIONS: Rates of hs-CRP testing are very low, but higher among those seeing a cardiologist or having private insurance. Those who received a high potency statin had higher rates of testing, suggesting that those with higher cardiovascular risk may be more likely to receive an hs-CRP test.
PCV13 THE UTILISATION AND EFFECTIVENESS OF ANTITHROMBOTIC AGENTS FOR PREVENTING DEEP VEIN THROMBOSIS AFTER TOTAL HIP REPLACEMENT-A CASE STUDY IN SOUTHERN TAIWAN
Yu YY 1 , Chen LC 1 , Chien SH 2 1 Kaohsiung Medical University, Kaohsiung, Taiwan, 2 Kaohsiung Medical University Hospital, Kaohsiung, Taiwan OBJECTIVES: Antithrombotic therapy is effective in preventing thromboembolic diseases, and it has been recommended by several international guidelines to prevent deep vein thrombosis (DVT) after major orthopedic surgeries under carefully monitoring bleeding risks. To establish Taiwanese local guidance, this case study aims to evaluate the current utilization and effectiveness of antithrombotic agents for preventing DVT after total hip replacement (THR). METHODS: This one-year retrospective cohort study was conducted at a medical center in Southern Taiwan from May 2008 to April 2009. Adult patients (above 18 years) who had undergone primary THR were identified by inpatient electronic database. Their medical records were reviewed from surgery date to three months post-operation for collecting demographic details and DVT-related clinical symptoms as the surrogate of effectiveness. Descriptive statistic and time-to-event analysis were then conducted. RESULTS: Medical records of 82 patients (57.32% women) were reviewed. The average age is 59.15 ± 13.43 years and the mean body mass index is 25.20 ± 4.86 kg/m 2 . Only 31 out of the 82 patients (37.80%) had ever received prophylactic antithrombotic agents after surgery and all of them used aspirin, but only 22 patients used aspirin for more than 10 days. Twelve patients presented DVT symptoms after surgery but only one is from prophylactic group. Independent relative risk of DVT for patients without prophylaxis is 8.25 folds of patients with prophylaxis (95% confidence interval: 1.48, 154.91). DVT symptoms mainly (91.67%) occurred within 15 days after THR and the median duration to symptoms presentation is 12 days. CONCLUSIONS: Antithrombotic therapy is not commonly used to prevent DVT after THR in this medical center. Aspirin alone seems effectively reduces the risk of DVT-related symptoms. It is necessary to further investigate the effectiveness of prophylactic antithrombotic agents after THR from Taiwanese population-based database and explore the potential genetic factors influencing the effectiveness of antithrombotic therapy. Comparative effectiveness research identifies superior clinical devices or treatments through head-to-head comparisons. This study describes the use of an innovative framework to assess the quality and safety of two INR Point of Care devices. METHODS: Patients enrolled in the hematology Anticoagulation Management Service provided three INR measures: one venous sample analyzed by our lab (considered the standard measure), one fingerstick analyzed by the Hemochron Signature Elite POC device and another fingerstick by the Coaguchek XS Plus. Agreement between INR values from each device and the lab was assessed. Agreement was achieved when the INR measures were predicted by a novel, validated method to lead to the same clinical decision. Differences in agreement between the POC devices and the lab were assessed using McNemar's test of paired proportions. RESULTS: Ninetynine subjects were enrolled into the study. There was significantly less difference between INR values from the Coaguchek XS device and the lab compared to the Hemochron device (average absolute difference = 0.24 vs 0.41 p < 0.05). The Hemochron device tended to report both high and low INR values were within the target range when the laboratory said otherwise. Consequently, the Hemochron device was significantly more likely to lead to a different clinical decision than the core laboratory compared to the Coaguchek XS (30% vs. 18%, respectively; RR: 1.7, 95% CI: 1.1-2.4, P = 0.007). CONCLUSIONS: Comparative effectiveness analysis can provide essential information to make informed decisions when selecting medical devices to
PCV14 COMPARATIVE EFFECTIVENESS ANALYSIS IDENTIFIES A SUPERIOR POINT OF CARE DEVICE FOR ASSESSING THE INTERNATIONAL NORMALIZED RATIO
